Marx-Gross, Susanne https://orcid.org/0000-0003-1831-0210
Winter, Anne J.
Wollschlaeger, Daniel
Preussner, Paul-Rolf
Funding for this research was provided by:
Pharmaceuticals Bayer
Article History
Received: 8 January 2025
Accepted: 4 March 2025
First Online: 29 March 2025
Declarations
:
: Anne J Winter, Daniel Wollschlaeger, and Paul-Rolf Preussner declare that they have no competing interests regarding this work. Susanne Marx-Gross declares that she has no competing interests regarding this work; outside the submitted work, she reports grants from Bayer AG.
: It was not necessary to obtain an ethics vote as this was a retrospective data analysis of patients’ reports between 2013 and 2019. The data collection began in 2019. All the data were analyzed pseudonymously, and the principles of the Declaration of Helsinki were respected. If only health data are evaluated retrospectively that are routinely collected at the clinic/department (neither additional study-related surveys nor study-related examinations are carried out), so-called “third parties” are not given access to the data, and the data are passed on and published exclusively in anonymous form; neither consultation with the ethics committee nor informed consent from the patients is necessary. This procedure is regulated in Rhineland-Palatinate by the State Hospital Act (§ 36 and § 37). Landesärztekammer Rheinland-Pfalz.